Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
1001-1020 of 3,900 trials

Preventing Diabetes After Kidney Transplant: GLP-1 Medication Study

We are testing whether GLP-1 receptor agonists can help reverse metabolic syndrome in patients on the kidney transplant waiting list. This study will evaluate changes in health and safety over 3 to 6 months.

Metabolic Syndrome in Kidney Transplant Patients3-6 monthsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesEndocrinologyNephrology

Preventing Diabetes After Kidney Transplant: GLP-1 Treatment Study

We are studying whether a new medication can help prevent diabetes in patients immediately after receiving a kidney transplant. This trial looks at various health effects and safety over time.

Post-Kidney Transplant Diabetes>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesDiabetologyNephrology

Ulcerative Colitis: Comparing Ustekinumab and Infliximab

We are studying whether a combination of two treatments helps people with moderate to severe ulcerative colitis achieve remission better than using each treatment alone.

Ulcerative Colitis>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesGastroenterologyInternal Medicine

Chronic Kidney Disease: Baxdrostat with Dapagliflozin

We are studying whether the combination of baxdrostat and dapagliflozin is more effective than dapagliflozin alone for adults with chronic kidney disease and high blood pressure. The trial will assess its impact on kidney health and heart-related risks.

Chronic Kidney DiseaseHypertension>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementCardiologyInternal MedicineNephrology

Repotrectinib for Advanced Cancers in Kids and Young Adults

We are studying a new treatment for children and young adults with advanced cancers that have specific genetic changes. The trial aims to evaluate how well it works and its safety.

Advanced Solid Tumors>2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesOncologyPediatrics

Advanced Cancer: JNJ-87704916 Tumor-Targeting Virus

We are testing a new virus that targets tumors in patients with advanced cancer. The goal is to see if it can effectively attack cancer cells when injected directly into the tumor.

Advanced Solid Tumors>2 yearsSafety phase (I)Oncology

Chronic Inflammatory Demyelinating Polyneuropathy: Riliprubart Study

We are testing the new medication riliprubart in people with CIDP who haven't found relief from usual treatments. The study will help us understand its effects on disability, quality of life, and safety.

Chronic Inflammatory Demyelinating Polyneuropathy6-12 monthsConfirmation phase (III)Post-Trial Drug AccessStandard MedicinesCost ReimbursementNeurology

Parkinson’s Disease vs. Multiple System Atrophy: Imaging Study

We are comparing two imaging methods to see which one better identifies Parkinson’s disease and multiple system atrophy. This may help improve diagnosis for patients with these conditions.

Parkinson's DiseaseAlzheimer's DiseaseMultiple Systems Atrophy - Parkinsonian Variant>2 yearsEfficacy phase (II)Confirmation phase (III)NeurologyOtolaryngology

Liver Transplant: Low-Dose Arginine-Vasopressin Study

We are investigating whether low-dose arginine-vasopressin can reduce kidney injury after liver transplantation. This study aims to improve recovery and outcomes for transplant patients.

Acute Kidney InjuryLiver Transplantation≤3 monthsConfirmation phase (III)≤5 visitsNo PlaceboInvestigational MedicinesHepatologyNephrology

Fasudil for Early Alzheimer's Disease

We are studying whether fasudil can help prevent memory loss in people with early Alzheimer's disease. The trial will also assess its safety and effects on brain health.

Alzheimer's DiseaseCognitive ImpairmentEfficacy phase (II)6-10 visitsInvestigational MedicinesPartially RemoteNeurologyPsychiatry

Colorectal Cancer: Amivantamab Treatment Study

We are studying the effects of amivantamab alone and with standard chemotherapy for patients with advanced colorectal cancer. The goal is to see how well it works and to ensure it is safe.

Advanced or Metastatic Colorectal CancerSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteOncology

Parkinson's Disease: AAV2-GDNF Treatment Study

We are studying a new therapy to see if it can improve motor symptoms in adults with moderate Parkinson's Disease. The trial also looks at safety and overall quality of life for participants.

Parkinson's Disease>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesNeurology

Healthy Men: Study of Inno8 Dosing

We are researching how different doses of the medicine Inno8 work in the bodies of healthy men. This study may help us understand the best dosing for future treatments.

Haemophilia A1-2 yearsSafety phase (I)AllergologyDermatologyDiabetologyEndocrinologyGynecology and ObstetricsHematologyInfectious DiseasesInternal MedicineNephrologyNeurologyOncologyOphthalmologyOrthopedics and TraumatologyOtolaryngologyPediatricsPsychiatryRheumatologyUrology

Severe Hemophilia A: Continued Access to Efanesoctocog Alfa

We are providing ongoing treatment access for patients with severe hemophilia A who completed a previous trial with efanesoctocog alfa. The study aims to gather more information on its safety and effectiveness in preventing and treating bleeding episodes.

Haemophilia AConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteHematologyInternal Medicine

Metastatic Lung Cancer: BL-B01D1 Treatment

We are evaluating a new treatment for patients with metastatic or unresectable non-small cell lung cancer and other solid tumors. The study aims to assess its safety and how well it is tolerated.

Non-small Cell Lung Cancer1-2 yearsSafety phase (I)OncologyPulmonology

Teicoplanin for Infection Prevention in Pediatric AML

We are studying whether teicoplanin can help prevent serious infections in children newly diagnosed with acute myeloid leukemia. This trial will assess its safety and effectiveness during their treatment.

Acute Myeloid Leukemia>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesInfectious DiseasesOncology

Atopic Dermatitis: Long-Term Study of Amlitelimab

We are evaluating the long-term safety and effectiveness of amlitelimab for individuals with moderate to severe atopic dermatitis who have participated in earlier studies. This research aims to better understand how the treatment works over time.

Atopic Dermatitis>2 yearsEfficacy phase (II)Confirmation phase (III)>20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteAllergologyDermatology

Propranolol for Anxiety in Pancreatic Cancer Surgery

We are studying whether propranolol can help reduce anxiety in patients undergoing surgery for pancreatic cancer and if it affects tumor-related changes. This trial will compare the effects of propranolol to a placebo in a small group of participants.

Pancreatic Cancer>2 yearsEfficacy phase (II)Standard MedicinesGastroenterologyInternal MedicineOncology

New Imaging Tracer for Liver and GI Diseases

We are investigating a special imaging agent in healthy people and patients with liver and gastrointestinal conditions. This study aims to see how effectively it binds to specific receptors related to these diseases.

Crohn’s DiseasePrimary Sclerosing CholangitisMetabolic Dysfunction-Associated Steatotic Liver DiseaseSafety phase (I)GastroenterologyHepatologyInternal Medicine

Acute Myeloid Leukemia: CLN-049 Treatment Study

We are testing a new treatment called CLN-049 for patients with acute myeloid leukemia who have measurable residual disease. This study aims to find the right dose and assess its safety.

Acute Myeloid Leukemia>2 yearsSafety phase (I)HematologyOncology